Yang Liang 2025-10-08 17:35:22
43380
According to DoNews on October 8, Changfeng Pharmaceutical Co., Ltd. (hereinafter referred to as “Changfeng Pharmaceutical”) was officially listed on the main board of the Hong Kong Stock Exchange with the stock code “2652”. This global offering was 41.198 million shares, of which the Hong Kong public offering received 6,697.80 times subscription, becoming the second highest-over-purchase new stock since the implementation of the revised new stock pricing mechanism of the Hong Kong Stock Exchange in August this year. As of 9:55, Changfeng Pharmaceutical reported at HK$44.42 per share, up 201.15% from the issue price, with a market value of over HK$18.3 billion.
Changfeng Pharmaceutical’s comprehensive product portfolio covers many treatment areas with high clinical needs, such as asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis, which can meet the needs of most patients and medical institutions for respiratory diseases and other related diseases, and achieve coverage of multiple specialties such as respiratory, pediatrics, internal medicine, emergency department, otolaryngology and critical care medicine.
Among them, CF017 is a budesonide suspension for inhalation for the treatment of bronchial asthma, and is the highest-selling inhalation drug category in China. CF018 Nitrostin Fluticasone Nasal Spray is used to treat moderate to severe allergic rhinitis. It was included in the medical insurance catalog in December 2023 and quickly increased its sales. The sales in the first quarter of 2025 (10.34 million yuan) have reached 43.3% of the sales in the whole year of 2024.
In addition, Changfeng Pharmaceutical has a number of late-stage and approval stage products, such as the compound preparation CF006/CF043, which has completed registered clinical trials in China (treatment of bronchial asthma and COPD). Changfeng Pharmaceutical, as the only company in China to develop salmeterol/fluticasone aerosol (MDI), is expected to fill the market gap of the original drug Seretide®; in addition, GW008/GW013, as the world’s first tiotropium bromide soft aerosol (SMI), aims at the global market of the original drug Spiriva®. Through innovative dosage forms to improve patient compliance, have been developed simultaneously in China, the United States and Europe, and is expected to become a new treatment path for COPD.
Since its establishment, Changfeng Pharmaceutical has obtained investments from many well-known institutions such as Gaotejia Investment, Jishi Capital, Yuanyi Investment, Jinpu Investment, and CICC Capital.
